<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37953820</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2328-8957</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Open forum infectious diseases</Title><ISOAbbreviation>Open Forum Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Risk of New-Onset Long COVID Following Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2: A Community-Based Cohort Study.</ArticleTitle><Pagination><StartPage>ofad493</StartPage><MedlinePgn>ofad493</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ofad493</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ofid/ofad493</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Little is known about the risk of long COVID following reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We estimated the likelihood of new-onset, self-reported long COVID after a second SARS-CoV-2 infection, compared to a first infection.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We included UK COVID-19 Infection Survey participants who tested positive for SARS-CoV-2 between 1 November 2021 and 8 October 2022. The primary outcome was self-reported long COVID 12-20 weeks after each infection. Separate analyses were performed for those &lt;16 years and &#x2265;16 years. We estimated adjusted odds ratios (aORs) for new-onset long COVID using logistic regression, comparing second to first infections, controlling for sociodemographic characteristics and calendar date of infection, plus vaccination status in participants &#x2265;16 years of age.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Overall, long COVID was reported by those &#x2265;16 years after 4.0% and 2.4% of first and second infections, respectively; the corresponding estimates among those aged &lt;16 years were 1.0% and 0.6%. The aOR for long COVID after second compared to first infections was 0.72 (95% confidence interval [CI], .63-.81) for those &#x2265;16 years and 0.93 (95% CI, .57-1.53) for those &lt;16 years.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">The risk of new-onset long COVID after a second SARS-CoV-2 infection is lower than that after a first infection for persons aged &#x2265;16 years, though there is no evidence of a difference in risk for those &lt;16 years. However, there remains some risk of new-onset long COVID after a second infection, with around 1 in 40 of those aged &#x2265;16 years and 1 in 165 of those &lt;16 years reporting long COVID after a second infection.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bosworth</LastName><ForeName>Matthew L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Data and Analysis for Social Care and Health Division, Office for National Statistics, Newport, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shenhuy</LastName><ForeName>Boran</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Methodology and Quality Directorate, Office for National Statistics, Newport, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>A Sarah</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>National Institute for Health Research Health Protection Research Unit in Healthcare-Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nafilyan</LastName><ForeName>Vah&#xe9;</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-0160-217X</Identifier><AffiliationInfo><Affiliation>Data and Analysis for Social Care and Health Division, Office for National Statistics, Newport, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Public Health, Environment and Society, London School of Hygiene and Tropical Medicine, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alwan</LastName><ForeName>Nisreen A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>School of Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton National Health Service Foundation Trust, Southampton, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Hara</LastName><ForeName>Margaret E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Long Covid Support, Registered Charity, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayoubkhani</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-6352-0394</Identifier><AffiliationInfo><Affiliation>Data and Analysis for Social Care and Health Division, Office for National Statistics, Newport, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Open Forum Infect Dis</MedlineTA><NlmUniqueID>101637045</NlmUniqueID><ISSNLinking>2328-8957</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-COVID condition</Keyword><Keyword MajorTopicYN="N">reinfection</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. M. E. O. has received Patient Involvement honorarium for speaking at a Long COVID Physio International Forum panel discussion. N. A. A. is a Long Covid Kids Charity Champion, and a Long Covid Support Charity Advisor, and has contributed in an advisory capacity to the World Health Organization and European Union Commission's Expert Panel on effective ways of investing in health meetings in relation to post-COVID condition. All other authors report no potential conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>13</Day><Hour>4</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37953820</ArticleId><ArticleId IdType="pmc">PMC10633780</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofad493</ArticleId><ArticleId IdType="pii">ofad493</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhang &#xa0;H, Zang &#xa0;C, Xu &#xa0;Z, et al. &#xa0;Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes. Nat Med &#xa0;2022; 29:226&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9873564</ArticleId><ArticleId IdType="pubmed">36456834</ArticleId></ArticleIdList></Reference><Reference><Citation>
Office for National Statistics . Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 2 February 2023. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/2february2023. Accessed 2 February 2023.</Citation></Reference><Reference><Citation>
Office for National Statistics . Coronavirus (COVID-19) Infection Survey, characteristics of people testing positive for COVID-19, UK: 16 November 2022. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveycharacteristicsofpeopletestingpositiveforcovid19uk/16november2022. Accessed 1 February 2023.</Citation></Reference><Reference><Citation>
Long Covid Support and Long Covid Kids . How do Covid reinfections affect long Covid? Results from an internet survey of people with Long Covid. 2022. Available at: https://www.longcovid.org/images/Documents/Reinfections_in_Long_Covid_Survey_Report_by_Long_Covid_Support_and_Long_Covid_Kids_080922.pdf. Accessed 1 February 2023.</Citation></Reference><Reference><Citation>Bowe &#xa0;B, Xie &#xa0;Y, Al-Aly &#xa0;Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med &#xa0;2022; 28:2398&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9671810</ArticleId><ArticleId IdType="pubmed">36357676</ArticleId></ArticleIdList></Reference><Reference><Citation>
Office for National Statistics . Coronavirus (COVID-19) Infection Survey: methods and further information. 2023. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/methodologies/covid19infectionsurveypilotmethodsandfurtherinformation. Accessed 17 August 2023.</Citation></Reference><Reference><Citation>
UK Health Security Agency . NHS test and trace statistics (England): methodology. 2022. Available at: https://www.gov.uk/government/publications/nhs-test-and-trace-statistics-england-methodology/nhs-test-and-trace-statistics-england-methodology. Accessed 1 February 2023.</Citation></Reference><Reference><Citation>Pritchard &#xa0;E, Matthews &#xa0;PC, Stoesser &#xa0;N, et al. &#xa0;Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nat Med &#xa0;2021; 27:1370&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8363500</ArticleId><ArticleId IdType="pubmed">34108716</ArticleId></ArticleIdList></Reference><Reference><Citation>
Office for National Statistics . Coronavirus (COVID-19) Infection Survey, characteristics of people testing positive for COVID-19, UK: 19 October 2022. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveycharacteristicsofpeopletestingpositiveforcovid19uk/19october2022#measuring-the-data. Accessed 1 February 2023.</Citation></Reference><Reference><Citation>
National Institute for Health and Care Excellence . COVID-19 rapid guideline: managing the long-term effects of COVID-19. 2021. Available at: https://www.nice.org.uk/guidance/ng188/. Accessed 17 August 2023.</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis &#xa0;HE, Assaf &#xa0;GS, McCorkell &#xa0;L, et al. &#xa0;Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine &#xa0;2021; 38:101019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen &#xa0;M, Manoharan &#xa0;L, Elkheir &#xa0;N, et al. &#xa0;Characterising long COVID: a living systematic review. BMJ Glob Health &#xa0;2021; 6:e005427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziauddeen &#xa0;N, Gurdasani &#xa0;D, O&#x2019;Hara &#xa0;ME, et al. &#xa0;Characteristics and impact of long Covid: findings from an online survey. PLoS One &#xa0;2022; 17:e0264331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903286</ArticleId><ArticleId IdType="pubmed">35259179</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization . A clinical case definition of post&#x2013;COVID-19 condition by a Delphi consensus. 2021. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1. Accessed 17 August 2023.</Citation></Reference><Reference><Citation>
Office for National Statistics . Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 1 September 2022. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1september2022. Accessed 17 August 2023.</Citation></Reference><Reference><Citation>
House of Commons Library . Coronavirus: Covid-19 booster vaccines frequently asked questions. 2023. Available at: https://commonslibrary.parliament.uk/research-briefings/cbp-9332/. Accessed 17 August 2023.</Citation></Reference><Reference><Citation>Austin &#xa0;PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res &#xa0;2011; 46:399&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3144483</ArticleId><ArticleId IdType="pubmed">21818162</ArticleId></ArticleIdList></Reference><Reference><Citation>
UK Government . Coronavirus (COVID-19) in the UK. 2023. Available at: https://coronavirus.data.gov.uk/. Accessed 29 March 2023.</Citation></Reference><Reference><Citation>Thompson &#xa0;EJ, Williams &#xa0;DM, Walker &#xa0;AJ, et al. &#xa0;Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun &#xa0;2022; 13:3528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9240035</ArticleId><ArticleId IdType="pubmed">35764621</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani &#xa0;D, Bosworth &#xa0;ML, King &#xa0;S, et al. &#xa0;Risk of long COVID in people infected with severe acute respiratory syndrome coronavirus 2 after 2 doses of a coronavirus disease 2019 vaccine: community-based, matched cohort study. Open Forum Infect Dis &#xa0;2022; 9:ofac464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9494414</ArticleId><ArticleId IdType="pubmed">36168555</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli &#xa0;M, Penfold &#xa0;RS, Merino &#xa0;J, et al. &#xa0;Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis &#xa0;2022; 22:43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe &#xa0;A, Iwagami &#xa0;M, Yasuhara &#xa0;J, et al. &#xa0;Protective effect of COVID-19 vaccination against long COVID syndrome: a systematic review and meta-analysis. Vaccine &#xa0;2023; 41:1783&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9905096</ArticleId><ArticleId IdType="pubmed">36774332</ArticleId></ArticleIdList></Reference><Reference><Citation>Byambasuren &#xa0;O, Stehlik &#xa0;P, Clark &#xa0;J, et al. &#xa0;Effect of covid-19 vaccination on long covid: systematic review. BMJ Med &#xa0;2023; 2:e000385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9978692</ArticleId><ArticleId IdType="pubmed">36936268</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Forecasting Team . Past SARS-CoV-2 infection protection against reinfection: a systematic review and meta-analysis. Lancet &#xa0;2023; 401:833&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9998097</ArticleId><ArticleId IdType="pubmed">36930674</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobrovitz &#xa0;N, Ware &#xa0;H, Ma &#xa0;X, et al. &#xa0;Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the Omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis &#xa0;2023; 23:556&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10014083</ArticleId><ArticleId IdType="pubmed">36681084</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng &#xa0;J, Ma &#xa0;Y, Liu &#xa0;Q, et al. &#xa0;Severity and outcomes of SARS-COV-2 reinfection compared with primary infection: a systematic review and meta-analysis. Int J Environ Res Public Health &#xa0;2023; 20:3335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9961977</ArticleId><ArticleId IdType="pubmed">36834029</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki &#xa0;A, Putrino &#xa0;D. Why we need a deeper understanding of the pathophysiology of long COVID. Lancet Infect Dis &#xa0;2023; 23:393&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9928485</ArticleId><ArticleId IdType="pubmed">36967698</ArticleId></ArticleIdList></Reference><Reference><Citation>
Office for National Statistics . Comparing self-reported morbidity with electronic health records, England: 2021. Available at: &#xa0;https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/comparingselfreportedmorbiditywithelectronichealthrecordsengland/2021. Accessed 17 August 2023.</Citation></Reference><Reference><Citation>Pantelic &#xa0;M, Ziauddeen &#xa0;N, Boyes &#xa0;M, et al. &#xa0;Long Covid stigma: estimating burden and validating scale in a UK-based sample. PLoS One &#xa0;2022; 17:e0277317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9683629</ArticleId><ArticleId IdType="pubmed">36417364</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker &#xa0;AJ, MacKenna &#xa0;B, Inglesby &#xa0;P, et al. &#xa0;Clinical coding of long COVID in English primary care: a federated analysis of 58 million patient records in situ using OpenSAFELY. Br J Gen Pract &#xa0;2021; 71:e806&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8340730</ArticleId><ArticleId IdType="pubmed">34340970</ArticleId></ArticleIdList></Reference><Reference><Citation>
Department of Health and Social Care . First UK cases of Omicron variant identified. 27 November 2021. Available at: https://www.gov.uk/government/news/first-uk-cases-of-omicron-variant-identified. Accessed 7 March 2023.</Citation></Reference><Reference><Citation>
Office for National Statistics . Self-reported long COVID after infection with the Omicron variant in the UK: 18 July 2022. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/selfreportedlongcovidafterinfectionwiththeomicronvariant/18july2022. Accessed 1 February 2023.</Citation></Reference><Reference><Citation>Antonelli &#xa0;M, Pujol &#xa0;JC, Spector &#xa0;TD, et al. &#xa0;Risk of long COVID associated with Delta versus Omicron variants of SARS-CoV-2. Lancet &#xa0;2022; 399:2263&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>